GlassScriptPhysician profile
Muhammad U Alam
NPI 1164628400
$548.16
in general payments reported to CMS, 2019-2025
13 companies · $64.76 in 2025
The $64.76 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.62 · 2020: $101 · 2021: $93.20 · 2022: $72.53 · 2023: $136 · 2024: $13.38 · 2025: $64.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $142.02 | 2019-2025 | Trelegy Ellipta, Nucala |
| Actelion Pharmaceuticals US, INC. | $80.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.23 | 2019-2021 | |
| Electromed, INC. | $56.72 | 2021-2023 | Smartvest |
| Philips North America LLC | $43.61 | 2020-2021 | |
| Genzyme Corporation | $31.75 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $29.97 | 2023-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $23.12 | 2020 | |
| Grifols USA, LLC | $22.26 | 2020 | |
| Inogen, INC. | $14.37 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Verona Pharma, INC. | $14.19 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $14.11 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Astrazeneca Pharmaceuticals LP | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.